Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center

Bone Marrow Transplant. 2016 Aug;51(8):1140-2. doi: 10.1038/bmt.2016.67. Epub 2016 Apr 4.

Authors

L Philippe¹, P Helias², M Puyraveau³, H Boulahdour⁴, E Deconinck¹, E Daguindau¹

Affiliations

¹ Department of Hematology, University Hospital, UMR 1098, Besançon, France.
² Department of Oncology, University Hospital, Pointe-a-Pitre, Guadeloupe, France.
³ Department of Clinical methodologies, University Hospital, Besançon, France.
⁴ Department of Nuclear Medicine, University Hospital, Besançon, France.

PMID: 27042844
DOI: 10.1038/bmt.2016.67

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Antigens, CD20 / immunology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carmustine / therapeutic use
Cytarabine / therapeutic use
Etoposide / therapeutic use
Female
Follow-Up Studies
France
Hematopoietic Stem Cell Transplantation / methods*
Humans
Lymphoma, Mantle-Cell / drug therapy
Lymphoma, Mantle-Cell / mortality
Lymphoma, Mantle-Cell / radiotherapy
Lymphoma, Mantle-Cell / therapy*
Lymphoma, Non-Hodgkin / mortality
Lymphoma, Non-Hodgkin / therapy
Male
Melphalan / therapeutic use
Middle Aged
Radioimmunotherapy / methods
Radioimmunotherapy / mortality
Survival Analysis
Transplantation Conditioning / adverse effects
Transplantation Conditioning / methods*
Transplantation, Autologous
Treatment Outcome
Yttrium Radioisotopes / therapeutic use*

Substances

Antibodies, Monoclonal
Antigens, CD20
Yttrium Radioisotopes
Cytarabine
ibritumomab tiuxetan
Etoposide
Melphalan
Carmustine

Supplementary concepts

BEAM regimen